Interações de Metilergometrina

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (bula de Almotriptana, Contraindicações)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Interações medicamentosas)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (bula de Bupivacaína, Advertências e precauções)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (bula de Bupivacaína + epinefrina, Advertências e precauções)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (bula de Cloroprocaína, Advertências)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (bula de Eletriptana, Contraindicações)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (bula de Frovatriptana, Contraindicações)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (bula de Lidocaína + epinefrina, Advertências e precauções)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (bula de Mepivacaína, Advertências)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (bula de Naratriptana, Contraindicações)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (bula de Nitroglicerina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

…Precautions (5.5)] • Ischemic bowel disease [see Warnings and Precautions (5.5)] • Uncontrolled hypertension [see Warnings and Precautions (5.8)] • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1,… (bula de Sumatriptana, Contraindicações)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (bula de Sumatriptana + naproxeno, Contraindicações)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (bula de Metilergometrina, Interações medicamentosas)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (bula de Zolmitriptana, Contraindicações)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

…drugs Tricyclic antidepressants Angiotensin, aldosterone Atropine Steroids, such as hydrocortisone Norepinephrine transporter inhibitors, such as atomoxetine Ergot alkaloids, such as methylergonovine maleate 7.2 Interactions that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists… (bula de Fenilefrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (bula de Lidocaína, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (bula de Primaquina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (bula de Metilergometrina, Advertências)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (bula de Metilergometrina, Interações medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (bula de Metilergometrina, Interações medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (bula de Metilergometrina, Interações medicamentosas)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (bula de Metilergometrina, Interações medicamentosas)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (bula de Metilergometrina, Interações medicamentosas)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (bula de Metilergometrina, Interações medicamentosas)

Pressor Effect with Concomitant Oxytocic Drugs Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [ see Drug Interactions (7) ]. (bula de Efedrina, Advertências e precauções)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (bula de Epinefrina (adrenalina), Interações medicamentosas)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (bula de Metilergometrina, Interações medicamentosas)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (bula de Metilergometrina, Advertências)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (bula de Metilergometrina, Interações medicamentosas)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (bula de Metilergometrina, Interações medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in patients treated with ergot-derived dopaminergic agents. (bula de Pramipexol, Advertências e precauções)

Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (bula de Prilocaína + epinefrina, Interações medicamentosas)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (bula de Metilergometrina, Interações medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (bula de Ropinirol, Advertências e precauções)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (bula de Metilergometrina, Interações medicamentosas)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (bula de Metilergometrina, Advertências)